XNASTWST
Market cap2.60bUSD
Jan 10, Last price
43.60USD
1D
-3.37%
1Q
-1.96%
IPO
209.22%
Name
Twist Bioscience Corp
Chart & Performance
P/E
—
P/S
8.30
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.13%
Rev. gr., 5y
41.91%
Revenues
313m
+27.69%
Net income
-209m
L+2.01%
CFO
-64m
L-55.01%
Earnings
Jan 31, 2025
Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | |
| Income | |||||||||
Revenues | 312,974 27.69% | 245,109 20.41% | 203,565 53.83% | ||||||
Cost of revenue | 270,477 | 452,012 | 452,586 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 42,497 | (206,903) | (249,021) | ||||||
NOPBT Margin | 13.58% | ||||||||
Operating Taxes | 560 | 1,152 | (10,411) | ||||||
Tax Rate | 1.32% | ||||||||
NOPAT | 41,937 | (208,055) | (238,610) | ||||||
Net income | (208,726) 2.01% | (204,618) -6.08% | (217,863) 43.24% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (3,975) | (4,405) | 262,068 | ||||||
BB yield | 0.15% | 0.38% | -13.80% | ||||||
| Debt | |||||||||
Debt current | 29,610 | 14,896 | 13,642 | ||||||
Long-term debt | 155,247 | 173,242 | 176,182 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 407 | 475 | 60 | ||||||
Net debt | (91,542) | (148,275) | (316,716) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (64,094) | (142,474) | (124,385) | ||||||
CAPEX | (5,076) | (27,779) | (101,857) | ||||||
Cash from investing activities | (3,071) | 50,612 | (232,930) | ||||||
Cash from financing activities | 6,890 | 911 | 270,534 | ||||||
FCF | 86,033 | (216,323) | (346,446) | ||||||
| Balance | |||||||||
Cash | 276,399 | 336,413 | 504,968 | ||||||
Long term investments | 1,572 | ||||||||
Excess cash | 260,750 | 324,158 | 496,362 | ||||||
Stockholders' equity | (1,242,430) | (1,033,790) | (830,259) | ||||||
Invested Capital | 1,815,357 | 1,751,766 | 1,710,955 | ||||||
ROIC | 2.35% | ||||||||
ROCE | 7.42% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 58,016 | 56,885 | 53,885 | ||||||
Price | 45.18 123.00% | 20.26 -42.51% | 35.24 -67.06% | ||||||
Market cap | 2,621,163 127.43% | 1,152,490 -39.31% | 1,898,907 -63.21% | ||||||
EV | 2,529,621 | 1,004,215 | 1,582,191 | ||||||
EBITDA | 73,929 | (177,593) | (232,507) | ||||||
EV/EBITDA | 34.22 | ||||||||
Interest | 29 | 5 | 80 | ||||||
Interest/NOPBT | 0.07% | ||||||||